Tests in mice show the particles are better than MRI and CT at tracking cancer's progress
Researchers funded by the National Institute Biomedical Imaging and Bioengineering (NIBIB), a part of the National Institutes of Health (NIH), have developed florescent nanoparticles that light up to track the progress of breast cancer metastasis. They are currently testing the particles in mice with the hope of someday being able to use them in humans.
Prabhas Moghe, Ph.D., professor of Biomedical Engineering, and Chemical and Biochemical Engineering at Rutgers University, and his team are developing nanoparticles that can help identify and track cancer metastasis early on, even when the tumor is incredibly small. They have started with targeting the most common places to which breast cancer spreads, the lungs, adrenal glands, and bones. By changing the molecule that the nanoparticles are attached to, the researchers are able to create specialized “targeted” nanoparticles that seek out different organs. The fluorescent nanoparticles, made of rare earth metals, are encapsulated by albumin, forming Rare-Earth Albumin Nanocomposites (ReANCs). The albumin, a protein commonly found in blood, makes the engineered nanoparticles safe in animals. These ReANCs are engineered to emit infrared light. Infrared light is invisible to the human eye but can be seen with special detectors and cameras.
The team was able to create a “cocktail” combining all the different targeted ReANCs that could be combined in one injection—making it simple to illuminate of all the common sites of cancer metastasis at once. So far, the tests in mice have shown the nanoparticles to be more successful than both MRI and CT scans at identifying newly metastasized tumors in bones. It has not yet reached the gold standard of PET scans, but it does avoid exposing the subject to the radiation involved in PET imaging and is far less expensive than PET.
“There are still significant hurdles to be overcome before this imaging technique could be used in humans, but it is an important step in moving optical imaging cancer diagnosis forward,” said Behrouz Shabestari, Ph.D., director of the NIBIB program in Optical Imaging and Spectroscopy. “It has the potential to help doctors to identify tiny cancer cells and track their spread more effectively, leading to early detection and potentially improved treatment planning.”
In addition to tracking the spread of cancer, the nanoparticles could potentially be used to differentiate cancer tissue from healthy tissue for surgeons who are removing tumors. Moghe and his team hope that the technology could be positioned for use in humans within the next decade.